Intralesional Cancer Immunotherapies

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• Solid tumors with limited T-cell presence exhibit poor response to immune checkpoint inhibitors.
• Effective anti-tumor immunity requires T-cell infiltration, driven by innate immune responses.
• Dendritic cell activation and cross-presentation are crucial for T-cell mediated tumor antigen recognition.

Purpose of the Study:

• To explore strategies for enhancing T-cell infiltration in non-inflamed solid tumors.
• To investigate the role of innate immune stimulation in overcoming resistance to immunotherapy.
• To identify therapeutic approaches that can induce a favorable tumor microenvironment for immune checkpoint inhibitors.

Main Methods:

• Review of existing literature on tumor immunology and immunotherapy.
• Analysis of mechanisms underlying innate immune activation and T-cell priming.
• Evaluation of intralesional therapies, including oncolytic viruses and immune agonists.

Main Results:

• Intratumoral administration of oncolytic viruses, cytokines, or Toll-like receptor agonists can stimulate innate immunity.
• These stimuli promote type I interferon production, dendritic cell maturation, and cross-presentation of tumor antigens.
• Successful induction of these pathways can lead to increased T-cell infiltration and improved anti-tumor responses.

Conclusions:

• Intralesional therapies offer a promising strategy to overcome immune resistance in solid tumors.
• By triggering innate immune responses, these therapies can enhance the efficacy of immune checkpoint inhibitors.
• Targeting the tumor microenvironment to promote T-cell inflammation is critical for advancing cancer immunotherapy.